Literature DB >> 22250258

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.

Mari Wataya-Kaneda, Mari Tanaka, Ayumi Nakamura, Shoji Matsumoto, Ichiro Katayama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22250258     DOI： 10.1001/archderm.148.1.138

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  12 in total

1.  Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

Authors:  Mary Kay Koenig; Cynthia S Bell; Adelaide A Hebert; Joan Roberson; Joshua A Samuels; John M Slopis; Patti Tate; Hope Northrup
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

2.  Rapamycin, Autophagy, and Alzheimer's Disease.

Authors:  Zhiyou Cai; Liang-Jun Yan
Journal:  J Biochem Pharmacol Res       Date:  2013-06

3.  Peripheral tissular analysis of rapamycin's effect as a neuroprotective agent in vivo.

Authors:  Alfredo Gonzalez-Alcocer; Yareth Gopar-Cuevas; Adolfo Soto-Dominguez; Maria de Jesus Loera-Arias; Odila Saucedo-Cardenas; Roberto Montes de Oca-Luna; Humberto Rodriguez-Rocha; Aracely Garcia-Garcia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-07-27       Impact factor: 3.195

Review 4.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

5.  Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.

Authors:  Mary Kay Koenig; Adelaide A Hebert; Joan Roberson; Joshua Samuels; John Slopis; Audrey Woerner; Hope Northrup
Journal:  Drugs R D       Date:  2012-09-01

Review 6.  Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.

Authors:  Teguh Haryo Sasongko; Nur Farrah Dila Ismail; Nik Mohamad Ariff Nik Abdul Malik; Z A M H Zabidi-Hussin
Journal:  Orphanet J Rare Dis       Date:  2015-08-12       Impact factor: 4.123

7.  Do you know this syndrome?

Authors:  Gabriela Maria Abreu Gontijo
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

8.  A quantitative increase in regulatory T cells controls development of vitiligo.

Authors:  Shilpak Chatterjee; Jonathan M Eby; Amir A Al-Khami; Myroslawa Soloshchenko; Hee-Kap Kang; Navtej Kaur; Osama S Naga; Anuradha Murali; Michael I Nishimura; I Caroline Le Poole; Shikhar Mehrotra
Journal:  J Invest Dermatol       Date:  2013-12-23       Impact factor: 8.551

Review 9.  Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Authors:  Romina Moavero; Antonella Coniglio; Francesco Garaci; Paolo Curatolo
Journal:  Ital J Pediatr       Date:  2013-09-17       Impact factor: 2.638

10.  Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type.

Authors:  Vishalakshi Viswanath; Parul Thakur; Poonam Pund
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.